查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1722413

2025 年至 2033 年血红素病市场报告（按类型、治疗、测试类型、最终用户和地区）

Hemoglobinopathies Market Report by Type, Treatment, Test Type, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3个工作天内

价格

2024 年全球血红素病市场规模达 110 亿美元。展望未来， IMARC Group预计到 2033 年市场规模将达到 222 亿美元，2025-2033 年期间的成长率 (CAGR) 为 8.16%。製药公司、医疗保健提供者和研究机构之间不断加强的策略合作和伙伴关係、向个人化医疗的日益转变以及监管支持和优惠报销政策的实施是推动市场成长的关键因素。

血红蛋白病是一组影响血红蛋白分子的遗传性疾病，而血红素分子对于红血球在全身输送氧气的正常功能至关重要。这些疾病主要可分为两种类型：地中海贫血和异常血红蛋白变体，例如镰状细胞性贫血。地中海贫血是由于基因突变导致构成血红蛋白的其中一条珠蛋白链的生成减少，从而引起失衡并随后出现贫血。另一方面，镰状细胞性贫血等疾病是由导致血红蛋白分子本身形状或功能异常的突变引起的。异常形状会导致红血球变得僵硬，使其难以穿过小血管，进而影响氧气分布。它们通常是遗传的，可导致从轻微到严重的症状，包括疲劳、虚弱，在极端情况下还会导致器官损伤。

公众意识的不断增强是推动全球市场发展的主要动力。专注于血红蛋白疾病的组织在游说政策变革、资金和改善患者护理方面越来越有效。它们对于教育大众也至关重要，从而增加早期诊断和治疗。随着医疗保健系统变得更加健全和便捷，诊断和治疗血红蛋白病等特殊疾病的能力也随之增强。新的诊所和医院正在配备先进的诊断技术，从而涵盖更大的患者群体。除此之外，製药公司、医疗保健提供者和研究机构之间的策略合作和伙伴关係也在推动血红蛋白病产业的发展。此外，对个人化医疗的日益重视是另一个对血红蛋白病市场产生正面影响的因素。个人化医疗涉及根据患者的个别特征制定医疗方案。个人化医疗的转变正在影响对专门诊断测试和治疗的需求，进一步推动市场成长。此外，监管支持和有利的报销政策的实施正在创造积极的市场前景。

血红素病市场趋势/驱动因素：

血红素异常盛行率不断上升

推动血红蛋白疾病产业发展的最重要驱动因素之一是镰状细胞性贫血、地中海型贫血和其他罕见变异等血红蛋白疾病的盛行率不断上升。这些疾病在特定的种族和地理区域中普遍存在，但由于全球移民模式，它们在更广泛的人群中越来越普遍。历史上发病率较低的国家现在报告的病例增加，需要改善医疗基础设施来管理这些疾病。随着认识的增强和诊断率的提高，对专门治疗、诊断和管理计划的需求也相应增加。此外，越来越多的医疗保健提供者正在接受识别和治疗血红蛋白疾病的培训，从而进一步促进市场成长。所有这些因素都导致对药物、诊断设备、基因检测试剂盒以及针对血红蛋白疾病的专业医疗服务的需求增加，从而推动了该行业的发展。

诊断和治疗的技术进步

血红蛋白疾病产业的另一个重要驱动力是诊断方法和治疗技术的进步。透过新生儿筛检和包括高效能液相层析 (HPLC) 和分子技术在内的先进诊断工具进行早期诊断可以更好地控制病情。除此之外，基因治疗、CRISPR 技术和改进的药物配方等治疗方法的进步也为更有效地治疗血红蛋白疾病铺平了道路。这些创新不仅改善了患者的治疗效果，也为市场参与者投资研发提供了动力。随着技术的发展，我们可以预见更准确、更快捷的诊断工具和潜在的治癒疗法，从而推动行业更大的需求和扩张。

政府措施和资金

政府的努力也是血红蛋白病产业的重要市场驱动力。世界各国政府越来越认识到血红蛋白异常对公共卫生的影响，并正在製定有针对性的计画来应对这一问题。此外，资助研究、进行公众意识宣传活动以及将血红蛋白病筛检纳入国家医疗保健计划都是此类倡议的例子。这些措施不仅提高了诊断率，而且使更多人能够接受治疗。也为製药公司和研究机构提供开发治疗方法的特别补助和财政支持。这些措施和资金注入极大地增强了该行业的供需，促进了市场成长。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

  • 概述
  • 主要行业趋势

第五章：全球血红素疾病市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场细分：依类型

  • 地中海型贫血
    • 关键部分
      • α地中海贫血
      • β地中海型贫血
  • 镰形血球贫血症
  • 其他的

第七章：市场区隔：依处理方式

  • 输血
  • 干细胞移植
  • 止痛药
  • 抗生素
  • 血管紧张素转换酶抑制剂
  • 羟基脲
  • 其他的

第八章：市场区隔：依测试类型

  • 红血球（RBC）计数
  • 基因检测
  • 高效液相层析法（HPLC）
  • 血红素等电聚焦 (Hb IEF)
  • 血红素电泳（Hb ELP）
  • 血红素溶解度测试

第九章：市场区隔：依最终用户

  • 医院和诊所
  • 诊断实验室
  • 其他的

第十章：市场细分：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场区隔：依国家

第 11 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 12 章：价值链分析

第 13 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 14 章：价格分析

第 15 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Bio-Rad Laboratories Inc.
    • bluebird bio Inc.
    • Bristol-Myers Squibb Company
    • Danaher Corporation
    • Emmaus Life Sciences Inc.
    • Gamida-Cell Ltd.
    • Global Blood Therapeutics Inc.
    • Novartis AG
    • PerkinElmer Inc.
    • Pfizer Inc.
    • Prolong Pharmaceuticals LLC
    • Sangamo Therapeutics Inc.
    • Sysmex Corporation
Product Code: SR112025A5123

The global hemoglobinopathies market size reached USD 11 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 22.2 Billion by 2033, exhibiting a growth rate (CAGR) of 8.16% during 2025-2033. The rising strategic collaborations and partnerships among pharmaceutical companies, healthcare providers, and research institutions, the growing shift toward personalized medicine, and the implementation of regulatory support and favorable reimbursement policies are among the key factors driving the market growth.

Hemoglobinopathies are a group of genetic disorders that affect the hemoglobin molecule, which is crucial for the proper function of red blood cells in carrying oxygen throughout the body. These disorders can be categorized mainly into two types: thalassemias and abnormal hemoglobin variants, such as sickle cell anemia. Thalassemias result from mutations that reduce the production of one of the globin chains that make up hemoglobin, leading to an imbalance and subsequent anemia. On the other hand, conditions such as sickle cell anemia are caused by mutations that lead to abnormal shapes or functions of the hemoglobin molecule itself. The abnormal shapes can cause red blood cells to become rigid, making it difficult for them to travel through small blood vessels, thereby affecting oxygen distribution. They are often inherited and can result in symptoms ranging from mild to severe, including fatigue, weakness, and in extreme cases, organ damage.

The growing public awareness majorly drives the global market. Organizations focused on hemoglobinopathies are increasingly effective at lobbying for policy changes, funding, and improved patient care. They are also crucial in educating the public, thereby increasing early diagnosis and treatment. As healthcare systems become more robust and accessible, the capability to diagnose and treat specialized conditions, such as hemoglobinopathies also increases. New clinics and hospitals are being equipped with advanced diagnostic technologies, thereby reaching a larger patient population. Along with this, strategic collaborations and partnerships among pharmaceutical companies, healthcare providers, and research institutions are also driving the growth of the hemoglobinopathies industry. In addition, the growing emphasis on personalized medicine is another factor that impacts the hemoglobinopathies market positively. Personalized medicine involves tailoring medical treatment to individual patient characteristics. The shift toward personalized medicine is influencing the demand for specialized diagnostic tests and treatments, further driving market growth. Moreover, the implementation of regulatory support and favorable reimbursement policies is creating a positive market outlook.

Hemoglobinopathies Market Trends/Drivers:

Increasing prevalence of hemoglobin disorders

One of the most significant drivers propelling the hemoglobinopathies industry is the rising prevalence of hemoglobin disorders such as sickle cell anemia, thalassemias, and other rare variants. These disorders are prevalent in specific ethnic groups and geographical regions, but due to global migration patterns, they are increasingly found in a more widespread population. Countries with historically low incidence rates are now reporting more cases, necessitating improved healthcare infrastructure to manage these conditions. As awareness grows and diagnosis rates increase, there is a corresponding rise in demand for specialized treatments, diagnostics, and management plans. Additionally, more healthcare providers are being trained to recognize and treat hemoglobinopathies, further facilitating market growth. All these factors contribute to increased needs for medication, diagnostics equipment, genetic testing kits, and specialized healthcare services tailored for hemoglobinopathies, thereby driving the industry's growth.

Technological advancements in diagnosis and treatment

Another significant driver for the hemoglobinopathies industry is the technological advancements in both diagnostic methods and treatments. Earlier diagnosis through newborn screenings and sophisticated diagnostic tools including High-Performance Liquid Chromatography (HPLC) and molecular techniques have led to better management of the condition. Along with this, advancements in treatment methods, including gene therapy, CRISPR technology, and improved drug formulations, are also paving the way for more effective management of hemoglobin disorders. These innovations not only enhance patient outcomes but also provide an impetus for market players to invest in research and development. As the technology evolves, we can anticipate more accurate, quicker diagnostic tools and potentially curative therapies, driving greater demand and expansion in the industry.

Government Initiatives and Funding

Governmental efforts are also significant market drivers for the hemoglobinopathies industry. Various governments worldwide are increasingly acknowledging the public health impact of hemoglobin disorders and are setting up targeted programs to deal with them. In addition, funding for research, public awareness campaigns, and inclusion of hemoglobinopathy screening in national healthcare plans are examples of such initiatives. These steps not only increase the rate of diagnosis but also make treatments more accessible to a larger population. Special grants and financial support for pharmaceutical companies and research institutions for developing treatments are also available. Such initiatives and financial injections into the sector significantly bolster both demand and supply, facilitating market growth.

Hemoglobinopathies Industry Segmentation:

Breakup by Type:

  • Thalassemia
    • Alpha Thalassemia
    • Beta Thalassemia
  • Sickle Cell Disease
  • Others

Sickle cell disease accounts for the majority of the market share

The market for treating sickle cell disease (SCD), a type of hemoglobinopathy, is experiencing robust growth due to the rising incidence and awareness of SCD, particularly in African, Middle Eastern, and South Asian populations. Additionally, advancements in diagnostic techniques, including high-performance liquid chromatography (HPLC) and genetic screening are enabling earlier and more accurate detection, increasing the demand for targeted treatments. In addition, government initiatives have also played a pivotal role by incorporating SCD screenings in national healthcare plans and providing funding for research. In addition, the emergence of innovative treatment options such as gene therapies and CRISPR technology offer potential curative solutions, attracting significant investment in the sector. Furthermore, positive regulatory frameworks and reimbursement policies make treatments more accessible, thereby expanding the market.

Breakup by Treatment:

  • Blood Transfusion
  • Stem-cell Transplantation
  • Analgesics
  • Antibiotics
  • ACE Inhibitors
  • Hydroxyurea
  • Others

The demand for blood transfusion treatment in the hemoglobinopathies industry is primarily driven by its essential role in managing severe cases of disorders, such as thalassemia and sickle cell disease. Along with this, the increasing prevalence of these conditions amplifies the need for regular transfusions, thereby fueling market growth. In addition, technological advancements in blood screening and storage have also contributed to safer and more efficient transfusion processes. Governmental initiatives, such as organized blood donation campaigns and reimbursement policies, make this treatment more accessible and cost-effective for patients. In addition, the growing interest in stem-cell transplantation as a potentially curative treatment for hemoglobinopathies, including thalassemia and sickle cell disease is a notable market driver. Moreover, technological advancements have made these procedures safer and more effective, drawing increased investment and research focus. Governmental backing in the form of grants and regulatory approval fast-tracks also bolster this sector.

On the other hand, the growing awareness and advocacy for advanced treatment options have led to higher demand for stem-cell transplantation, further propelling market growth in the hemoglobinopathies industry. Apart from this, the demand for analgesics in the hemoglobinopathies industry is driven by chronic pain. Increasing awareness and diagnosis rates further provide a boost to this market segment. The need for antibiotics in the hemoglobinopathies industry is driven by frequent bacterial infections in patients, thereby stimulating the demand for effective treatment options. Furthermore, the market for ACE inhibitors in the hemoglobinopathies industry is propelled by their role in managing kidney complications in patients.

Breakup by Test Type:

  • Red Blood Cell (RBC) Count
  • Genetic Testing
  • High Performance Liquid Chromatography (HPLC)
  • Hemoglobin Isoelectric Focusing (Hb IEF)
  • Hemoglobin Electrophoresis (Hb ELP)
  • Hemoglobin Solubility Test

In the hemoglobinopathies industry, the market drivers for the red blood cell (RBC) count test type are significant. Hemoglobinopathies, including conditions, such as sickle cell anemia and thalassemia, necessitate frequent monitoring of RBC counts to assess disease severity and treatment efficacy. As awareness of these disorders grows, so does the demand for accurate diagnostic tools. Moreover, advancements in healthcare technology have led to more accessible and cost-effective RBC count testing methods. The combination of increased disease awareness and improved diagnostic capabilities positions the RBC count test as a critical component of the hemoglobinopathies industry, driving its market growth. Along with this, genetic testing is a key market driver in the hemoglobinopathies industry, enabling precise disease identification and personalized treatment strategies, and fostering growth and innovation.

On the other hand, high-performance liquid chromatography (HPLC) is a crucial driver in the hemoglobinopathies industry, providing precise hemoglobin analysis, enhancing diagnostics, and fostering industry advancement. Apart from this, hemoglobin isoelectric focusing (Hb IEF) plays a pivotal role in the hemoglobinopathies industry by offering precise hemoglobin analysis, driving diagnostic accuracy, and industry growth. In confluence with this, hemoglobin electrophoresis (Hb ELP) is a cornerstone in the hemoglobinopathies industry, providing precise hemoglobin analysis, driving diagnostic accuracy, and fostering industry growth. Furthermore, hemoglobin solubility testing is a critical driver in the hemoglobinopathies industry, offering efficient diagnosis and aiding in disease management, contributing to industry growth.

Breakup by End User:

  • Hospitals and Clinics
  • Diagnostics Laboratories
  • Others

Diagnostics laboratories serve as a pivotal end user in the hemoglobinopathies industry, driving growth due to their central role in disease diagnosis and management. In addition, the increasing prevalence of hemoglobinopathies worldwide necessitates a higher volume of diagnostic tests, including hemoglobin analysis and genetic testing. Furthermore, ongoing research and development efforts focus on enhancing the accuracy and efficiency of diagnostic tools, further elevating the significance of diagnostics laboratories. Their expertise and technology contribute significantly to advancing our understanding of hemoglobin disorders and tailoring treatment approaches, solidifying their status as key market drivers in this industry.

On the contrary, hospitals and clinics represent crucial end users in the hemoglobinopathies industry, actively driving growth and advancement. These healthcare facilities are frontline providers of care to individuals affected by hemoglobin disorders. The growing awareness of these conditions, coupled with an increasing patient population, leads to a higher demand for diagnostic tests, genetic counseling, and specialized treatments. Hospitals and clinics play a pivotal role in providing comprehensive care, driving the need for improved diagnostic tools and therapeutic interventions. Their prominence as end users reinforces their impact as significant market drivers in the hemoglobinopathies industry.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America leads the market, accounting for the largest hemoglobinopathies market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America stands as a dynamic and influential region in the hemoglobinopathies industry, driven by the region's commitment to healthcare excellence and rigorous standards. It fuels the demand for cutting-edge diagnostic tools and therapeutic interventions. The prevalence of hemoglobin disorders, particularly sickle cell disease, within diverse populations, including African Americans and Hispanic communities, places North America at the forefront of research, diagnosis, and treatment.

Additionally, the region's robust research and development ecosystem, consisting of academic institutions, pharmaceutical companies, and biotechnology firms, fosters innovation in hemoglobinopathy diagnostics and therapies. This research-driven environment continually introduces novel diagnostic methods and treatment modalities, stimulating market growth. Furthermore, advocacy efforts and government initiatives aimed at improving healthcare access for individuals with hemoglobinopathies amplify the demand for diagnostic testing and specialized care. These initiatives include newborn screening programs and policies supporting early diagnosis and intervention.

Competitive Landscape:

The key players are investing heavily in research and development to discover new diagnostic tests, therapies, and treatment modalities. They aim to enhance the accuracy of diagnostic tools and develop innovative treatments that can improve the quality of life for individuals with hemoglobin disorders. Along with this, companies are continually developing and improving diagnostic tests for hemoglobinopathies, including advancements in techniques, such as genetic testing, high-performance liquid chromatography (HPLC), hemoglobin electrophoresis (Hb ELP), and hemoglobin isoelectric focusing (Hb IEF) is positively influencing the market. In addition, pharmaceutical companies in the hemoglobinopathies market work on the development of new therapies, including gene therapies, gene editing technologies (e.g., CRISPR), and small molecule drugs, which act as another growth-inducing factor. Furthermore, the widespread adoption of cutting-edge technologies, such as artificial intelligence and machine learning, for data analysis and improving diagnostic accuracy is contributing to the market.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Bio-Rad Laboratories Inc.
  • bluebird bio Inc.
  • Bristol-Myers Squibb Company
  • Danaher Corporation
  • Emmaus Life Sciences Inc.
  • Gamida-Cell Ltd.
  • Global Blood Therapeutics Inc.
  • Novartis AG
  • PerkinElmer Inc.
  • Pfizer Inc.
  • Prolong Pharmaceuticals LLC
  • Sangamo Therapeutics Inc.
  • Sysmex Corporation

Key Questions Answered in This Report

  • 1.What was the size of the global hemoglobinopathies market in 2024?
  • 2.What is the expected growth rate of the global hemoglobinopathies market during 2025-2033?
  • 3.What has been the impact of COVID-19 on the global hemoglobinopathies market?
  • 4.What are the key factors driving the global hemoglobinopathies market?
  • 5.What is the breakup of the global hemoglobinopathies market based on the type?
  • 6.What is the breakup of the global hemoglobinopathies market based on the treatment?
  • 7.What are the key regions in the global hemoglobinopathies market?
  • 8.Who are the key players/companies in the global hemoglobinopathies market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hemoglobinopathies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Thalassemia
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Alpha Thalassemia
      • 6.1.2.2 Beta Thalassemia
    • 6.1.3 Market Forecast
  • 6.2 Sickle Cell Disease
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Treatment

  • 7.1 Blood Transfusion
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Stem-cell Transplantation
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Analgesics
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Antibiotics
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 ACE Inhibitors
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Hydroxyurea
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7 Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8 Market Breakup by Test Type

  • 8.1 Red Blood Cell (RBC) Count
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Genetic Testing
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 High Performance Liquid Chromatography (HPLC)
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Hemoglobin Isoelectric Focusing (Hb IEF)
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Hemoglobin Electrophoresis (Hb ELP)
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Hemoglobin Solubility Test
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Diagnostics Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Bio-Rad Laboratories Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 bluebird bio Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Bristol-Myers Squibb Company
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Danaher Corporation
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Emmaus Life Sciences Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Gamida-Cell Ltd.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
    • 15.3.7 Global Blood Therapeutics Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
    • 15.3.8 Novartis AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 PerkinElmer Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Pfizer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Prolong Pharmaceuticals LLC
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
    • 15.3.12 Sangamo Therapeutics Inc.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13 Sysmex Corporation
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hemoglobinopathies Market: Major Drivers and Challenges
  • Figure 2: Global: Hemoglobinopathies Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Hemoglobinopathies Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Hemoglobinopathies Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Hemoglobinopathies Market: Breakup by Treatment (in %), 2024
  • Figure 6: Global: Hemoglobinopathies Market: Breakup by Test Type (in %), 2024
  • Figure 7: Global: Hemoglobinopathies Market: Breakup by End User (in %), 2024
  • Figure 8: Global: Hemoglobinopathies Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Hemoglobinopathies (Thalassemia) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Hemoglobinopathies (Thalassemia) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Hemoglobinopathies (Sickle Cell Disease) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Hemoglobinopathies (Sickle Cell Disease) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Hemoglobinopathies (Other Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Hemoglobinopathies (Other Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Hemoglobinopathies (Blood Transfusion) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Hemoglobinopathies (Blood Transfusion) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Hemoglobinopathies (Stem-cell Transplantation) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Hemoglobinopathies (Stem-cell Transplantation) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Hemoglobinopathies (Analgesics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Hemoglobinopathies (Analgesics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Hemoglobinopathies (Antibiotics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Hemoglobinopathies (Antibiotics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Hemoglobinopathies (ACE Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Hemoglobinopathies (ACE Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Hemoglobinopathies (Hydroxyurea) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Hemoglobinopathies (Hydroxyurea) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Hemoglobinopathies (Other Treatments) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Hemoglobinopathies (Other Treatments) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Hemoglobinopathies (Red Blood Cell (RBC) Count) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Hemoglobinopathies (Red Blood Cell (RBC) Count) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Hemoglobinopathies (Genetic Testing) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Hemoglobinopathies (Genetic Testing) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Hemoglobinopathies (High Performance Liquid Chromatography-HPLC) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Hemoglobinopathies (High Performance Liquid Chromatography-HPLC) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Hemoglobinopathies (Hemoglobin Isoelectric Focusing-Hb IEF) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Hemoglobinopathies (Hemoglobin Isoelectric Focusing-Hb IEF) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Hemoglobinopathies (Hemoglobin Electrophoresis-Hb ELP) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Hemoglobinopathies (Hemoglobin Electrophoresis-Hb ELP) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Hemoglobinopathies (Hemoglobin Solubility Test) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Hemoglobinopathies (Hemoglobin Solubility Test) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Global: Hemoglobinopathies (Hospitals and Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Global: Hemoglobinopathies (Hospitals and Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Global: Hemoglobinopathies (Diagnostics Laboratories) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Global: Hemoglobinopathies (Diagnostics Laboratories) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Global: Hemoglobinopathies (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Global: Hemoglobinopathies (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: North America: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: North America: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: United States: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: United States: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Canada: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Canada: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Asia-Pacific: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Asia-Pacific: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: China: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: China: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Japan: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Japan: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: India: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: India: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: South Korea: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: South Korea: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Australia: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Australia: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Indonesia: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Indonesia: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Others: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Europe: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Europe: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Germany: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Germany: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: France: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: France: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: United Kingdom: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: United Kingdom: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Italy: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Italy: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Spain: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Spain: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Russia: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Russia: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Others: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Latin America: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Latin America: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Brazil: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Brazil: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 89: Mexico: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 90: Mexico: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 91: Others: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 92: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 93: Middle East and Africa: Hemoglobinopathies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 94: Middle East and Africa: Hemoglobinopathies Market: Breakup by Country (in %), 2024
  • Figure 95: Middle East and Africa: Hemoglobinopathies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 96: Global: Hemoglobinopathies Industry: SWOT Analysis
  • Figure 97: Global: Hemoglobinopathies Industry: Value Chain Analysis
  • Figure 98: Global: Hemoglobinopathies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hemoglobinopathies Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Hemoglobinopathies Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Hemoglobinopathies Market Forecast: Breakup by Treatment (in Million USD), 2025-2033
  • Table 4: Global: Hemoglobinopathies Market Forecast: Breakup by Test Type (in Million USD), 2025-2033
  • Table 5: Global: Hemoglobinopathies Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 6: Global: Hemoglobinopathies Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Hemoglobinopathies Market: Competitive Structure
  • Table 8: Global: Hemoglobinopathies Market: Key Players